|Bid||43.03 x 800|
|Ask||47.00 x 800|
|Day's Range||42.85 - 44.22|
|52 Week Range||33.80 - 69.43|
|Beta (3Y Monthly)||2.22|
|PE Ratio (TTM)||18.34|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.20|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Cambrex Corporation...
Cambrex Corp NYSE:CBMView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is moderate for CBM with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold CBM had net inflows of $924 million over the last one-month. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Basic Materials sector is rising. The rate of growth is weak relative to the trend shown over the past year, but is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed a new 600 m2 facility at its site in Karlskoga, Sweden, which incorporates new laboratories for process and analytical development. The new, three-story building will incorporate process technology, QC and analytical development laboratories. The process technology laboratories will expand capacity providing an area where R&D and production teams can work together on scale up demonstration and technology transfer, including new capabilities in the scaling up of potent molecules requiring containment. The facility will employ computer modeling to optimize reactor set ups and plant conditions to improve technology transfer and the performance of existing processes.
EAST RUTHERFORD, N.J., May 29, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
Cambrex (CBM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cambrex (CBM) delivered earnings and revenue surprises of 17.65% and -0.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The East Rutherford, New Jersey-based company said it had net income of 31 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, came to 60 cents per share. The results ...
- Acquired Avista Pharma Solutions, broadening capabilities, enhancing revenue growth and expanding customer base - - Reaffirms full year financial guidance - - Conference.
EAST RUTHERFORD, N.J., April 30, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services.
Cambrex (CBM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had opened a new 120m2 quality control (QC) laboratory at its site in Paullo, Milan, Italy. The laboratory expands on the current QC facilities that analyze and test its generic API portfolio of products during development and manufacturing. The QC laboratory is now fully operational, having been authorized by the Agenzia Italiana Del Farmaco (AIFA).
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. For example, long term Ca...
Cambrex Corporation (CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA. The production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m3 and contain 4 reactors ranging from 200 to 1,000 gallon capacity enabling manufacturing campaigns of batch sizes up to 300 kg. With the completion of this new facility, the Charles City site now has the flexibility to support all phases of development and offer all scales of HPAPI manufacture across the full OEL band spectrum.
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
EAST RUTHERFORD, N.J., March 26, 2019 -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services.